Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644291 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02644291 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 16 participants.
The verdict
NCT02644291, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies. The drug mebendazole is an oral drug in a chewable 500 mg orange flavored tablet. It is already approved to treat parasitic infections. The purpose of this study is to determine the safety and side effects for increasing doses of mebendazole, followed by the treatment of an additional 12 patients at the best tolerated dose.
Interventions
- DRUG Mebendazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-05 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02644291
The ClinicalTrials.gov registry entry for NCT02644291 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mebendazole is the first listed.
NCT02644291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02644291 about?
NCT02644291 is a clinical study titled "Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors". This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies. The drug mebendazole is an oral drug in a chewable 500 mg orange flavored tablet. It is already approved ...
What is the current status of trial NCT02644291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-05. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT02644291?
The interventions under investigation include: Mebendazole (DRUG).
Who is sponsoring clinical trial NCT02644291?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.